Ironjustic
Mon, May-02-05, 06:19
Glycobiology. 2005 Mar 10; [Epub ahead of print] Related
Articles, Links
Advanced Glycation End Products & RAGE: A Common Thread in
Aging, Diabetes, Neurodegeneration & Inflammation.
Ramasamy R, Vannucci SJ, Shi Du Yan S, Herold K, Fang Yan S,
Marie Schmidt A.
Department of Surgery, Columbia University Medical Center, New
York, New York 10032.
The products of nonenzymatic glycation and oxidation of
proteins and lipids, the Advanced Glycation End Products
(AGEs), accumulate in a wide variety of environments. AGEs may
be generated rapidly or over long-periods of time stimulated
by a range of distinct triggering mechanisms, thereby
accounting for their roles in multiple settings and disease
states. A critical property of AGEs is their ability to
activate RAGE, a signal transduction receptor of the
immunoglobulin superfamily. It is our hypothesis that due to
such interaction, AGEs impart a potent impact in the tissues,
stimulating processes linked to inflammation and its
consequences. We hypothesize that AGEs cause perturbation in a
diverse group of diseases, such as diabetes, inflammation,
neurodegeneration and aging. Thus, we propose that targeting
this pathway may represent a logical step in the
prevention/treatment of the sequelae of these disorders.
PMID: 15764591 [PubMed - as supplied by publisher]
--------------------------------------------------------------
-------------------
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004
Dec;148(2):131-3. Related Articles, Links
The antioxidant acetylcysteine reduces oxidative stress by
decreasing level of AOPPs.
Lazarova M, Stejskal D, Lacnak B, Vaclavik J, Adamovska S,
Ochmanova R, Hanak V, Skacelova M.
Department of Internal Medicine, Sternberk Hospital,
Czech Republic.
Oxidative stress and especially its connection with many
diseases has been discussed much recently. Among markers of
oxidative stress there appear new and quite specific ones
called advanced oxidation protein products (AOPPs). We tried
to influence the level of AOPPs by an antioxidant therapy with
. Fourteen individuals with many cardiovascular risk factors
were examined. All these patients were administered
acetylcysteine (NAC) 600
mg/day orally during 20 days. Before starting the therapy we
determined AOPP, albumin cobalt binding (ACB), glucose,
creatinine, urea, ALT, AST, cholesterol, LDL, HDL and
triglycerides values in peripheral venous blood in all
individuals. After finishing our intervention we determined
AOPP, ACB and glucose level again. Our results show a
statistically significant decrease in AOPP levels after
20-day N-acetylcysteine therapy (medians, initially 82.2,
at study end 74.3 umol/l, p = 0.039). We demonstrate a
significant decrease in AOPP levels after 20-day
N-acetylcysteine therapy in dose 600 mg/day.
PMID: 15744360 [PubMed - in process]
--------------------------------------------------------------
-------------------
http://www.oralchelation.net/data/ToxicMetals/data13f.htm
<<snip>> N-acetylcysteine also appears to have some clinical
usefulness as a chelating agent in the treatment of acute
heavy metal poisoning, both as an agent capable of protecting
the liver and kidney from damage and as an intervention to
enhance elimination of the metals. <<snip>>
Who loves ya. Tom Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore DEAD
PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
Articles, Links
Advanced Glycation End Products & RAGE: A Common Thread in
Aging, Diabetes, Neurodegeneration & Inflammation.
Ramasamy R, Vannucci SJ, Shi Du Yan S, Herold K, Fang Yan S,
Marie Schmidt A.
Department of Surgery, Columbia University Medical Center, New
York, New York 10032.
The products of nonenzymatic glycation and oxidation of
proteins and lipids, the Advanced Glycation End Products
(AGEs), accumulate in a wide variety of environments. AGEs may
be generated rapidly or over long-periods of time stimulated
by a range of distinct triggering mechanisms, thereby
accounting for their roles in multiple settings and disease
states. A critical property of AGEs is their ability to
activate RAGE, a signal transduction receptor of the
immunoglobulin superfamily. It is our hypothesis that due to
such interaction, AGEs impart a potent impact in the tissues,
stimulating processes linked to inflammation and its
consequences. We hypothesize that AGEs cause perturbation in a
diverse group of diseases, such as diabetes, inflammation,
neurodegeneration and aging. Thus, we propose that targeting
this pathway may represent a logical step in the
prevention/treatment of the sequelae of these disorders.
PMID: 15764591 [PubMed - as supplied by publisher]
--------------------------------------------------------------
-------------------
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004
Dec;148(2):131-3. Related Articles, Links
The antioxidant acetylcysteine reduces oxidative stress by
decreasing level of AOPPs.
Lazarova M, Stejskal D, Lacnak B, Vaclavik J, Adamovska S,
Ochmanova R, Hanak V, Skacelova M.
Department of Internal Medicine, Sternberk Hospital,
Czech Republic.
Oxidative stress and especially its connection with many
diseases has been discussed much recently. Among markers of
oxidative stress there appear new and quite specific ones
called advanced oxidation protein products (AOPPs). We tried
to influence the level of AOPPs by an antioxidant therapy with
. Fourteen individuals with many cardiovascular risk factors
were examined. All these patients were administered
acetylcysteine (NAC) 600
mg/day orally during 20 days. Before starting the therapy we
determined AOPP, albumin cobalt binding (ACB), glucose,
creatinine, urea, ALT, AST, cholesterol, LDL, HDL and
triglycerides values in peripheral venous blood in all
individuals. After finishing our intervention we determined
AOPP, ACB and glucose level again. Our results show a
statistically significant decrease in AOPP levels after
20-day N-acetylcysteine therapy (medians, initially 82.2,
at study end 74.3 umol/l, p = 0.039). We demonstrate a
significant decrease in AOPP levels after 20-day
N-acetylcysteine therapy in dose 600 mg/day.
PMID: 15744360 [PubMed - in process]
--------------------------------------------------------------
-------------------
http://www.oralchelation.net/data/ToxicMetals/data13f.htm
<<snip>> N-acetylcysteine also appears to have some clinical
usefulness as a chelating agent in the treatment of acute
heavy metal poisoning, both as an agent capable of protecting
the liver and kidney from damage and as an intervention to
enhance elimination of the metals. <<snip>>
Who loves ya. Tom Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore DEAD
PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking